Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Thank you to everyone who has made this important step forward possible.
The recent cardiovascular risk reduction indication for Wegovy may eventually affect coverage policies, but statutory changes would be needed for broader Medicare coverage
[1] Wegovy is now the worlds first and only GLP-1 receptor agonist to treat MASH and the and the second treatment ever authorized by the FDA for MASH
Customer support can help with questions about medication use, side effects, and dose adjustments
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
